Filing Details

Accession Number:
0001140361-23-051260
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-11-02 21:14:42
Reporting Period:
2023-10-31
Accepted Time:
2023-11-02 21:14:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1305253 Eiger Biopharmaceuticals Inc. EIGR Biological Products, (No Disgnostic Substances) (2836) 361004130
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1822491 Leen Kawas 1900 Avenue Of The Stars, #1000
Los Angeles CA 90067
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-10-31 11,987 $0.26 4,379,087 No 4 P Indirect See footnote.
Common Stock Acquisiton 2023-10-31 12,345 $0.26 4,391,432 No 4 P Indirect See footnote.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote.
No 4 P Indirect See footnote.
Footnotes
  1. Ms. Kawas controls Propel Bio Management LLC, a Delaware limited liability company ("Propel Management"). Ms. Kawas also shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Ms. Kawas, Propel Management and Propel General Partner act as the investment advisor to, or general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds acquired the referenced shares of Common Stock.
  2. Ms. Kawas expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest.